These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21395631)

  • 21. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).
    Mager DR; Iñiguez IR; Gilmour S; Yap J
    JPEN J Parenter Enteral Nutr; 2015 Jan; 39(1):73-84. PubMed ID: 23976771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.
    Barshop NJ; Sirlin CB; Schwimmer JB; Lavine JE
    Aliment Pharmacol Ther; 2008 Jul; 28(1):13-24. PubMed ID: 18397387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.
    Nobili V; Manco M; Devito R; Di Ciommo V; Comparcola D; Sartorelli MR; Piemonte F; Marcellini M; Angulo P
    Hepatology; 2008 Jul; 48(1):119-28. PubMed ID: 18537181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
    Huang Y; Fu JF; Shi HB; Liu LR
    Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
    Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
    Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
    Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
    J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
    Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2010 Dec; 61(6):705-10. PubMed ID: 21224501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevalence of nonalcoholic fatty liver disease and metabolic abnormalities in 387 obese children and adolescents in Beijing, China].
    Zhou X; Hou DQ; Duan JL; Sun Y; Cheng H; Zhao XY; Liu JT; Yang P; Shan XY; Mi J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2013 May; 34(5):446-50. PubMed ID: 24016432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regular exercise coupled to diet regimen accelerates reduction of hepatic steatosis and associated pathological conditions in nonalcoholic fatty liver disease.
    Oh S; Tanaka K; Tsujimoto T; So R; Shida T; Shoda J
    Metab Syndr Relat Disord; 2014 Jun; 12(5):290-8. PubMed ID: 24689911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level.
    Huang SC; Yang YJ
    J Pediatr Gastroenterol Nutr; 2013 Feb; 56(2):145-50. PubMed ID: 22983378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease.
    Papandreou D; Karabouta Z; Pantoleon A; Rousso I
    Appetite; 2012 Dec; 59(3):939-44. PubMed ID: 23000278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of nigella sativa on various parameters in Patients of non-alcoholic fatty liver disease.
    Hussain M; Tunio AG; Akhtar L; Shaikh GS
    J Ayub Med Coll Abbottabad; 2017; 29(3):403-407. PubMed ID: 29076670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of total alkaloids of Rubus alceaefolius on oxidative stress in rats with non-alcoholic fatty liver disease].
    Zheng H; Zhao J; Liu Y; Zheng Y; Wu J; Hong Z
    Zhongguo Zhong Yao Za Zhi; 2011 Sep; 36(17):2383-7. PubMed ID: 22121808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver.
    Nobili V; Alisi A; Cutrera R; Carpino G; De Stefanis C; D'Oria V; De Vito R; Cucchiara S; Gaudio E; Musso G
    Thorax; 2015 Aug; 70(8):769-81. PubMed ID: 26069285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile.
    Quirós-Tejeira RE; Rivera CA; Ziba TT; Mehta N; Smith CW; Butte NF
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):228-36. PubMed ID: 17255837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.
    Gómez-Zorita S; Fernández-Quintela A; Macarulla MT; Aguirre L; Hijona E; Bujanda L; Milagro F; Martínez JA; Portillo MP
    Br J Nutr; 2012 Jan; 107(2):202-10. PubMed ID: 21733326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.